Literature DB >> 7935707

Fluoxetine.

L Gram1.   

Abstract

Fluoxetine was developed as an antidepressant drug. It is more effective than placebo, but a dose-effect relation has not been established. Fluoxetine is almost as effective as tricyclic antidepressant drugs, but the available studies do not allow accurate comparisons. Fluoxetine may be less effective than tricyclic antidepressant drugs for the treatment of inpatients with severe melancholic depression, and it should not be the first choice of a drug for them. Fluoxetine may be most appropriate for patients with moderate depression who can be treated as outpatients. If there is little improvement after treatment for four to six weeks, an alternative treatment should be offered. Fluoxetine does not have the anticholinergic, hypotensive, and sedative effects of tricyclic antidepressant drugs and has no particular cardiovascular effects; overdoses do not cause serious toxic effects. Nausea, anorexia, insomnia, and nervousness--the most common side effects--may be controlled with a careful adjustment to the dose. Clinically important drug interactions may occur with monoamine oxidase inhibitors, tricyclic antidepressant drugs, and other drugs. The published data on the antidepressant effect of fluoxetine do not fully explain its popularity. One may speculate that fluoxetine has psychobiologic effects not strictly related to the biology of depression and that it acts primarily as a mood- or affect-modulating agent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7935707     DOI: 10.1056/NEJM199411173312008

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  31 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Pharmacological treatment of depression in children and adolescents.

Authors:  R L Findling; M D Reed; J L Blumer
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

3.  Is bigger better? An argument for very low starting doses.

Authors:  James P McCormack; G Michael Allan; Adil S Virani
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 4.  Depression and myocardial infarction. Implications for medical prognosis and options for treatment.

Authors:  T J Cleophas
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 5.  New therapies for functional bowel diseases.

Authors:  B Coulie; M Camilleri
Journal:  Curr Gastroenterol Rep       Date:  2000-10

Review 6.  Crossover studies are a better format for comparing equivalent treatments than parallel-group studies.

Authors:  T J Cleophas; E M de Vogel
Journal:  Pharm World Sci       Date:  1998-06

7.  Re: CCNP position paper on the use of placebos in psychiatry.

Authors:  W C Friend; C Weijer
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

8.  Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy.

Authors:  Deblina Dey; Vipan K Parihar; Gergely G Szabo; Peter M Klein; Jenny Tran; Jonathan Moayyad; Faizy Ahmed; Quynh-Anh Nguyen; Alexandria Murry; David Merriott; Brandon Nguyen; Jodi Goldman; Maria C Angulo; Daniele Piomelli; Ivan Soltesz; Janet E Baulch; Charles L Limoli
Journal:  Radiat Res       Date:  2020-03-05       Impact factor: 2.841

Review 9.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.